Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CXM also running on news:
http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-newsArticle&ID=1391239&highlight=
Going to test $1 soon IMO. gltu
Agreed. Liking CXM a lot here. Huge upside potential.
CXM news:
The University Of Miami Is Enrolling Patients With Chronic Diabetic Foot Ulcers For MATRIX Clinical Trial
The University of Miami Department of Dermatology announced it is recruiting patients with slash extreme diabetic foot ulcers to participate in the MATRIX clinical trial. The MATRIX trial will turn over the effects of Excellarate™ (GAM501) (Ad5PDGF-B/bovine Quintessence I collagen gel) for the potential treatment of patients with neuropathic non-healing diabetic foot ulcers. Excellarate is an investigational artefact designed to stimulate the alter of wound healing.
The MATRIX (A Off 2b Study of GAM501 in the Treatment of Diabetic Ulcers in the Lop off Extremities) trial is a randomized, increase-smokescreen, placebo-controlled, comparator arm (standard of care) safe keeping and efficacy study to evaluate GAM501 (Ad5PDGF-B/bovine Specimen I collagen gel) that is topically administered once or twice throughout the speed of the study. The primary endpoint hand down be the effect of Excellarate on the incidence of flawless ulcer closure at 12 weeks or earlier.
“The Excellarate up to date gel using Gene Activated Matrix (GAM) technology is designed to provide localized and unchanged cellular release of platelet-derived growth factor-BB protein (PDGF-BB). Sustained delivery of PDGF-BB later on at the wound site is believed to stimulate angiogenesis and granulation tissue formation through the recruitment and build-up of chemotactic cells such as monocytes, fibroblasts, and endothelial cells, which are sure with a view the stimulation of a diversification of buried in healing processes,” stated Robert Kirsner, M.D., Ph.D., and a experiment investigator.
There are currently more than 20 million Americans who have diabetes and this number is expected to doppelgaenger by the year 2030. Many diabetic patients suffer from peripheral neuropathy, or a loss of feeling in their feet, that puts them at increased chance of foot ulceration. Over 850,000 chronic diabetic ulcers are diagnosed in the U.S. each year. Patients with non-healing ulcers are more susceptible to infections that may lead to amputation of the pretended foot or twit.
The University of Miami is among an estimated 25 sites participating in the MATRIX essay. The effort is expected to enroll 210 patients nationwide. Prospective participants can call the University of Miami Department of Dermatology and speak with Aliette Espinosa at 305-547-4282 for more advice about the study and eligibility.
University of Miami
http://keelingcauses.monhappyblog.com/2010/02/05/the-university-of-miami-is-enrolling-patients-with-chronic-diabetic-foot-ulcers-for-matrix-clinical-trial/
CYCC's Seliciclib (roscovitine) successful against estrogen-receptor-positive (ER+) breast cancers where letrozole was ineffective.
We challenged the aromatase-overexpressing cells with either the wild-type or the low forms of cyclin E and then treated them with the CDK2 inhibitor roscovitine," Keyomarsi said. "When we did that, we could kill all the cells."
http://insciences.org/article.php?articl...
CXM on breakout watch! Today just might be the day. Looks like it's done consolidating here in the low .60's. Should test .70 in the coming day(s).
CXM nice close @ HOD. Not many shares available down here. This one will fly with good news IMO.
CXM .62 break and running into the close.
CXM bid stacking here @ .61. Bottom is in.
Good post on CXM's potential w/Excellarate (see how this stacks up against the only other competitor):
Regranex Topical Gel - currently the only FDA-approved advanced care biologic topical agent for the treatment of patients with lower extremity neuropathic diabetic foot ulcers.
Excellarate is a collagen-based topical gel employing TRC's Gene Activated Matrix™ (GAM) technology to stimulate a patient's cells to produce a sustained micro-release of platelet-derived growth factor-B (PDGF-B) protein directly within the patient's wound where it is needed. TRC’s Gene Activated Matrix (GAM)technology provides a therapeutic level of protein synthesis at the site of tissue injury and has potential utility in several clinical indications where protein therapeutics have had limited success, including the treatment of dermal wounds (diabetic ulcers, venous stasis ulcers), therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease), and orthopedic products, including hard tissue (bone) and soft tissue (ligament, tendon and cartilage).
Regranex is patient administered, requires daily application followed by a daily cleansing 12 hours after the drug treatment over a 20-week period. As a result, during the prescribed 20-week treatment period, Regranex patients are required to undertake approximately 280 interventions (drug administrations and cleansings) to achieve the potential maximum healing effect.
Excellarate requires one or two physician administered treatment regimen.
Regranex - 50% of patients achieved complete wound closure in 20 weeks.
Excellarate - 83% of patients achieved complete wound closure in 14 weeks.
Regranex - Increase cancer risk in Patients
Excellarate - appears to be both safe and well tolerated, with no serious adverse events attributable to the study product.
The wound care market is projected to experience double digit growth over the next 3 to 5 years, with advanced wound care products comprising the fastest growing segment of the total wound care market. There are an estimated 91.3 million wounds in the U.S., which include 67.0 million surgical wounds, 17.6 million trauma wounds including burn injuries and amputations, 2.5 million pressure ulcers, 3.6 million diabetic ulcers and 3.3 million venous stasis and arterial ulcers. The ability to effectively address even a small proportion of these wounds would represent major new market opportunities for the Company's Gene Activated Matrix (GAM) technology.
In other words Excellerate will be the Number 1 topical gel for wound care which equals
PROFITS!!
Starter in CXM @ .61. Looks ready. Nice bottom play.
Joined you in CXM. Looks like a bottom reversal starting here.
Very smelly ones, to boot!!!
At the rate it's going, DEAR should be $2+ by EOW. Love these low floaters!
DEAR BV = 6.757, Trading @ 1.59. No Brainer here! Lots of upside potential!~
DEAR starting to run.
DEAR looks ready for another run. Just needs volume.
Agreed. Picked up a few DEAR today for the reversal.
10K holds through next week IMO. It's time for the market to bounce.
You're looking @ CTIC, not CYCC.
RPRX setting up for a big short squeeze here??? I think so. Added a few @ .87.
RPRX profit taking drying up here. Looking for the next leg up back to around $1+ this afternoon. HOD is 1.13.
In RPRX @ .98. Great news today. I love these low float bio's with a story to tell. This one should run bigtime in the coming days.
Repros' New IND for the Investigation of Androxal® in the Treatment of Type II Diabetes in Men with Secondary Hypogonadism is Now Effective
THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced that the Company has received verbal confirmation from the Division of Metabolic and Endocrine Drug Products of the Food and Drug Agency that the Company may initiate its Investigational New Drug Application for the study of oral Androxal® in the treatment of hypogonadal men with Type II Diabetes (T2D) with a Phase IIa trial. The FDA noted no clinical hold issues but added that it may have some comments on the specifics of the Phase II design. Doses to be tested in the Phase IIa study have been safely tested for longer durations in trials in men for the treatment of secondary hypogonadism.
“A Randomized, Parallel, Double-Blind, Placebo Controlled and Open-Label-Active-Controlled Exploratory Study to Evaluate the Efficacy of Androxal in Improving Glycemic Control in Men with Secondary Hypogonadism or Adult-Onset Idiopathic Hypogonadotrophic Hypogonadism (AIHH) and Type II Diabetes Mellitus”
The opening Phase IIa study is entitled, “A Randomized, Parallel, Double-Blind, Placebo Controlled and Open-Label-Active-Controlled Exploratory Study to Evaluate the Efficacy of Androxal in Improving Glycemic Control in Men with Secondary Hypogonadism or Adult-Onset Idiopathic Hypogonadotrophic Hypogonadism (AIHH) and Type II Diabetes Mellitus”. Repros plans to enroll a total of 60 men into three balanced parallel arms at several clinical sites comparing placebo to two active doses. The lead investigator for the study is Glenn R. Cunningham MD, Professor, Baylor College of Medicine, Division of Diabetes, Endocrinology & Metabolism, Departments of Medicine & Cellular Biology and the Medical Director, St. Luke’s Episcopal Hospital – Baylor Diabetes Program. Dr. Cunningham consulted with Repros in the development of the protocol.
To be included in the study men, age 20 to 80, must have been previously diagnosed with T2D mellitus as defined by the American Diabetes Association criteria for at least 6 months. The men must also have been receiving a stable dose of an oral hypoglycemic agent (OHA). The men must have a fasting serum glucose level of greater than 126 mg/dL but less than or equal to 220 mg/dL and HemoglobinA1c (HbA1c) between 7% and 9.5% while being treated with their prescribed OHA. The men must also exhibit a morning testosterone level of less than 300 ng/dL and a serum LH of between 1 and 8 mIU/ml.
Men will be treated for three months. The primary endpoints are the change in HbA1c from baseline to 3 months as well as the difference between placebo and the two active arms, the change in fasting blood glucose from baseline to months 1, 2, and 3 for each treatment group and the change in total testosterone from baseline to month 3.
In a 200 patient study of Androxal in hypogonadal men it was noted that fasting glucose levels were reduced in a significant manner in men whose glucose levels were greater than 104 mg/dL. It was further noted that the higher the glucose level the greater the reduction. This effect was noted in the group of men administered Androxal but not at the same rate in the placebo or topical testosterone treatment groups. Roughly 20% of the men in the 200 patient trial were previously diagnosed with diabetes and were receiving OHAs.
Wow, CRXX turning into a monster! Huge move today. I will take this type of move for the next 22 days. CRXX to $5 before FDA announcement??? $10+ after??? They sure have an impressive stable of promising drugs!
Hopefully holds .36. What a VERY frustrating stock but I am still holding. gltu
Picked up some CRXX @ 1.06. Nice support here @ 1.05.
Yup. RHIE has a BV OF $5.36 and is trading for under .40. Only a matter of time before this undiscovered gem gets noticed/accumulated by Institutions.
I thought that todays good news would send this one much higher. I am adding down here. This will run hard eventually, with only 3.5M in the float. There is a gap in the chart up to around $2.50.
gltu
More RHIE news out today:
http://www.c21media.net/news/detail.asp?area=89&article=53967
Only 3.5M in the float.
RHIE on watch for a big move today.
8-k filed last night that extends RHIE's forebearance agreement with their creditors (very nice news - reminds me of SIRI with a much smaller float).
http://biz.yahoo.com/e/100128/rhie8-k.html
Also, additional news out a few minutes ago regarding a new deal struck between RHIE and Seesaw:
http://www.c21media.net/news/detail.asp?area=89&article=53967
RHIE float of 3.5M. A few days of 5M+ shares traded and this one will be back over $1 in a hurry.
More RHIE news just out:
http://www.c21media.net/news/detail.asp?area=89&article=53967
RHIE on watch for a big move today.
8-k filed last night that extends RHIE's forebearance agreement with their creditors (very nice news).
http://biz.yahoo.com/e/100128/rhie8-k.html
Also, additional news out a few minutes ago regarding a new deal struck between RHIE and Seesaw:
http://www.c21media.net/news/detail.asp?area=89&article=53967
RHIE float of 3.5M. A few days of 5M+ shares traded and this one will be back over $1 in a hurry.
The "real run" for RHIE hasn't even started yet. I think that the real run will happen in February leading up to the Q4 10Q reporting (first week of March).
Did you see that the 2 analysts covering RHIE are forecasting average earnings of .46/share for Q4? Not bad for a stock trading for .41.
RHIE should already be trading closer to BV of $5.26. The chart shows a gap that needs to be filled back to around $2.50. I'm going to patiently hold this one for the big prize.
I also love the share structure with RHIE (only 3.5M in the float).
This has all the ingredients to be the next DEAR type runner.
gltu
RHIE making a move here off bottom. BV of $5.26 trading for .42. A steal down here IMO. With only 3.5M shares in the float, this one is set to make a monster move soon IMO. Looking for a move back to around $2.50 in the coming weeks.
RHIE making a move here off bottom. BV of $5.26 trading for .42. A steal down here IMO. With only 3.5M shares in the float, this one is set to make a monster move soon IMO. Looking for a move back to around $2.50 in the coming weeks.
RHIE's CEO hinted of a big upcoming 4th Q in the 3rd Q earnings announcement:
While customers remain cautious and are opting to defer some of their programming decisions, we do expect to deliver approximately 27 original films for the full year, the majority of which will be delivered in November and December.”
&
"Looking ahead, we remain confident in RHI’s business model and believe our efforts to improve performance will pay dividends for our business in the quarters ahead.”
http://finance.yahoo.com/news/RHI-Entertainment-Announces-bw-531831091.html?x=0&.v=1
With the majority of their 09' films being delivered in the 4th Q of 09'(November and December), that should result in outstanding financials for the 4th Q 09'.
RHIE also has an added incentive of having to get their share price above $1 by June. If their Q4 report is as good as I expect it to be, $1 should be a breeze. I am expecting a run much higher soon.
Keep this one on watch and gltu!
Patience should pay off nicely with RHIE. I am accumulating all I can down here. Just a matter of time before this one takes off. gltu
FWIW, Analysts expecting RHIE to report earnings of .46/share for 4th Q (should be out 1st week of March, per IR).
http://finance.yahoo.com/q/ae?s=RHIE
Not a bad QUARTERLY earnings projection for a stock trading for .37 (under the 4th Q earnings projection).
RHIE is grossly undervalued here and will be trading @ $2-$3 if earnings come in around (or better than) forecast. That is why I think RHIE has the potential to pull off a DEAR type run in the next month or so.
RHIE OS only 13M with a float of 4M (RHIE has a lower float than DEAR!). Time will tell.
It's out on Yahoo under Analyst estimates for current quarter - Dec 09':
http://finance.yahoo.com/q/ae?s=RHIE
Analysts expecting RHIE to report earnings of .46/share for 4th Q (should be out 1st week of March). Not a bad QUARTERLY earnings projection for a stock trading for .37 (under the 4th Q earnings projection).
RHIE is grossly undervalued here and will be trading @ $2-$3 if earnings come in around (or better than) forecast. That is why I think RHIE has the potential to pull off a DEAR type run in the next month or so. RHIE OS only 13M with a float of 4M (RHIE has a lower float than DEAR!). Time will tell.
RHIE bouncing off bottom here. Was over $10 a little over a year ago. A steal here @ .37. This will be the next DEAR type runner IMO. Low floater that doesn't take much buying pressure to push it higher.
RHIE is the next DEAR IMO - .40 TO $2+.
RHIE is working with their lenders to modify the terms of their lending agreement. We should get an update this week. If terms of the amended agreement are favorable (as I am confident they will be), RHIE will fly IMO.
With such a low float (w/the majority of the OS held by Insitutions/insiders), it won't take much to push this one back to $1+ with good news.
Rolled my DEAR profits into RHIE. RHIE is ready for an explosive move this week IMO. Keep on watch.